Periodontal pathogens on polytetrafluoroethylene membrane for guided tissue regeneration inhibit healing.
This study determined the microbial composition of the apical parts of the expanded polytetrafluoroethylene membrane surfaces facing the gingiva and the tooth in guided tissue regeneration. Microbial and clinical features of 2-to-3 wall periodontal bony defects treated with membranes with and without concomitant use of systemic Augmentin therapy were also determined. 18 patients with 18 study sites participated. 9 patients received systemic 500 mg Augmentin 1 h prior to surgery, and 500 mg TID for 8 days thereafter. 9 patients received no systemic antimicrobial therapy. Microbiological examination was performed 1 h prior to surgery, at the time of membrane removal at week 6, and at 6 months post-surgery. Microbial morphotypes, total viable counts, and the occurrence of selected microbial species were determined by phase-contrast microscopy, selective and non-selective culture, and DNA probes. Study sites were examined for probing pocket depths and attachment levels. At baseline, no microbial or clinical parameter showed statistical differences between groups. At 6 months, the Augmentin group demonstrated a significantly higher (P = 0.032; Student t-test) mean probing attachment gain (36.5% of potential gain to the cemento-enamel junction) than the 9 control patients (22.4% of potential gain). At the time of removal, membranes in the Augmentin group showed significantly fewer organisms than membranes in the control group (52.2 x 10(6) versus 488.6 x 10(6)). Sites free of pathogens on the membrane surface toward the tooth gained the most clinical attachment, even in the presence of various pathogens on the gingiva-facing membrane surface.(ABSTRACT TRUNCATED AT 250 WORDS)
Nowzari
H
H
University of Southern California, School of Dentistry, Department of Periodontology, University Park, Los Angeles 90089-0641, USA.
Matian
F
F
Slots
J
J
D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage / Q000627:therapeutic use; D019980:Amoxicillin-Potassium Clavulanate Combination; D019072:Antibiotic Prophylaxis; D001419:Bacteria / Q000145:classification / Q000235:genetics / Q000302:isolation & purification*; D002969:Clavulanic Acids / Q000008:administration & dosage / Q000627:therapeutic use; D015169:Colony Count, Microbial; D015342:DNA Probes; D004269:DNA, Bacterial / Q000032:analysis; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000627:therapeutic use; D004866:Equipment Contamination; D005260:Female; D005500:Follow-Up Studies; D017823:Furcation Defects / Q000473:pathology / Q000601:surgery*; D016557:Guided Tissue Regeneration, Periodontal; D006801:Humans; D008297:Male; D008567:Membranes, Artificial; D008858:Microscopy, Phase-Contrast; D008875:Middle Aged; D017622:Periodontal Attachment Loss / Q000473:pathology / Q000601:surgery; D010514:Periodontal Pocket / Q000473:pathology / Q000601:surgery; D010519:Periodontium / Q000382:microbiology* / Q000503:physiopathology; D011138:Polytetrafluoroethylene; D014945:Wound Healing
D002969:Clavulanic Acids; D015342:DNA Probes; D004269:DNA, Bacterial; D008567:Membranes, Artificial; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin; D011138:Polytetrafluoroethylene